{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:03:14Z","timestamp":1792083794884,"version":"4.4.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To review the current situation with respect to AMR in Vietnam and initiatives addressing it. Identifying areas where more information is required will provide a call to action to minimize any further rises in AMR within Vietnam and improve patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>National initiatives to address AMR in Vietnam, antibiotic use and prescribing, and availability of susceptibility data, in particular for the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines for CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) commonly used locally were also reviewed, plus local antibiotic availability. Insights from clinicians in Vietnam were sought to contextualize this information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In Vietnam there have been some initiatives addressing AMR; Vietnam was the first country in the Western Pacific Region to develop a national action plan to combat AMR, which according to the WHO is being implemented. Vietnam also has one of the highest rates of AMR in Asia due, in part, to the overuse of antimicrobial drugs, both in the animal health sector and in humans in both hospitals and the community. In addition, despite a 2005 law requiring antibiotic prescription, there is unrestricted access to over-the-counter antibiotics. Several global surveillance studies provide antibiotic susceptibility data for CA-RTI pathogens in Vietnam including Survey of Antibiotic Resistance (SOAR) and SENTRY (small isolate numbers only). For management of the common CA-RTIs in Vietnam there are several country-specific local antibiotic prescribing guidelines and in addition, there is a range of international guidelines referred to, but these may have been created based on pathogen resistance patterns that might be very different to those in Vietnam. Expert clinician opinion confirms the high resistance rates among common respiratory pathogens. A more standardized inclusive approach in developing local guidelines, using up-to-date surveillance data of isolates from community-acquired infections in Vietnam, could make management guideline use more locally relevant for clinicians. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development and improve clinical outcomes for patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac214","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T08:08:28Z","timestamp":1662451708000},"page":"i26-i34","source":"Crossref","is-referenced-by-count":36,"title":["Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome"],"prefix":"10.1093","volume":"77","author":[{"given":"Didem","family":"Torumkuney","sequence":"first","affiliation":[{"name":"GlaxoSmithKline , 980 Great West Road, Brentford, Middlesex TW8 9GS , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashri","family":"Kundu","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , 23 Rochester Park, 139234 Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giap Van","family":"Vu","sequence":"additional","affiliation":[{"name":"Respiratory Center, Bach Mai Hospital , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The National Centre for Drug Information and Adverse Drug Reactions Monitoring, Hanoi University of Pharmacy , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Van","family":"Pham","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy , 217 Hong Bang Street, Ward 11, District 5, Ho Chi Minh City , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kamble","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , 252, Dr Annie Besant Road, Worli, 400030 Mumbai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc","family":"Truong Ha Lan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Vietnam, Unit 701 , 235 Dong Khoi, District 1, Ho Chi Minh City , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergis","family":"Keles","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , B\u00fcy\u00fckdere Cad. No: 173, 1. Levent Plaza B Blok 34394 Levent, Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"2022090713493032300_dkac214-B1","article-title":"Antibiotic resistance\u2014fact sheet","author":"WHO","year":"2020"},{"issue":"Suppl 1","key":"2022090713493032300_dkac214-B2","article-title":"Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022","volume":"77","author":"Cant\u00f3n","year":"2022","journal-title":"J Antimicrobial Chemother"},{"key":"2022090713493032300_dkac214-B3","article-title":"Antimicrobial resistance\u2014fact sheet","author":"WHO","year":"2021"},{"key":"2022090713493032300_dkac214-B4","article-title":"Global action plan on antimicrobial resistance","author":"WHO","year":"2015"},{"key":"2022090713493032300_dkac214-B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41479-017-0031-4","article-title":"Encouraging rational antibiotic use in childhood pneumonia: a focus on Vietnam and the Western Pacific Region","volume":"9","author":"Phuong","year":"2017","journal-title":"Pneumonia (Nathan)"},{"key":"2022090713493032300_dkac214-B6","article-title":"Combating Antimicrobial Resistance in Vietnam","author":"CDC"},{"key":"2022090713493032300_dkac214-B7","article-title":"National Action Plan on Combatting Drug Resistance in the period from 2013-2020","author":"Vietnam Ministry of Health","year":"2013"},{"key":"2022090713493032300_dkac214-B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12889-020-8319-3","article-title":"The challenges of investigating antimicrobial resistance in Vietnam\u2014what benefits does a One Health approach offer the animal and human health sectors?","volume":"20","author":"Mitchell","year":"2020","journal-title":"BMC Public Health"},{"key":"2022090713493032300_dkac214-B9","article-title":"Global Database for the Tripartite Antimicrobial Resistance (AMR) Country Self-assessment Survey (TrACSS)","author":"WHO\/OIE\/FAO"},{"key":"2022090713493032300_dkac214-B10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240830","article-title":"Purchase and use of antimicrobials in the hospital sector of Vietnam, a lower middle income country with an emerging pharmaceuticals market","volume":"15","author":"Dat","year":"2020","journal-title":"PLoS One"},{"key":"2022090713493032300_dkac214-B11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgar.2019.06.002","article-title":"Antimicrobial susceptibility testing and antibiotic consumption results from 16 hospitals in Viet Nam: The VINARES project 2012\u20132013","volume":"18","author":"Vu","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"2022090713493032300_dkac214-B12","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/apa.15795","article-title":"Multi-drug resistance in Streptococcus pneumoniae among children in rural Vietnam more than doubled from 1999 to 2014","volume":"110","author":"Larsson","year":"2021","journal-title":"Acta Paediatr"},{"key":"2022090713493032300_dkac214-B13","doi-asserted-by":"crossref","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022090713493032300_dkac214-B14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13756-019-0671-7","article-title":"An estimation of total antimicrobial usage in humans and animals in Vietnam","volume":"9","author":"Carrique-Mas","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022090713493032300_dkac214-B15","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa048","article-title":"Community-level consumption of antibiotics according to the AWaRe (Access, Watch, Reserve) classification in rural Vietnam","volume":"2","author":"Nguyen","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"2022090713493032300_dkac214-B16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005875","article-title":"Drivers of antibiotic use in Vietnam: implications for designing community interventions","volume":"6","author":"McKinn","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2022090713493032300_dkac214-B17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/archdischild-2019-317733","article-title":"Antibiotic use in children hospitalised with pneumonia in Central Vietnam","volume":"105","author":"Nguyen","year":"2020","journal-title":"Arch Dis Child"},{"key":"2022090713493032300_dkac214-B18","first-page":"S83","article-title":"Microbial pathogens causing community acquired pneumonia in Vietnamese outpatients","volume":"51","author":"Pham","year":"2019","journal-title":"Infect Chemother"},{"key":"2022090713493032300_dkac214-B19","first-page":"2016","article-title":"Results from the Survey of Antibiotic Resistance (SOAR)","volume":"75","author":"Torumkuney","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022090713493032300_dkac214-B20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2022090713493032300_dkac214-B21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cmi.2019.03.007","article-title":"Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance","volume":"25","author":"Cusack","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022090713493032300_dkac214-B22","article-title":"Implementation of EUCAST breakpoints\/guidelines","author":"EUCAST","year":"2022"},{"key":"2022090713493032300_dkac214-B23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"2022090713493032300_dkac214-B24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"2022090713493032300_dkac214-B25","doi-asserted-by":"crossref","first-page":"i85","DOI":"10.1093\/jac\/dkw067","article-title":"Results from the Survey of Antibiotic Resistance (SOAR) 2002\u201309 in Turkey","volume":"71","author":"Torumkuney","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022090713493032300_dkac214-B26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1470-9465.2004.00862.x","article-title":"Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae","volume":"10","author":"Jacobs","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2022090713493032300_dkac214-B27","doi-asserted-by":"crossref","first-page":"i93","DOI":"10.1093\/jac\/dkw069","article-title":"Results from the Survey of Antibiotic Resistance (SOAR) 2009\u201311 in Vietnam","volume":"71","author":"Van","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022090713493032300_dkac214-B28","article-title":"SENTRY Antimicrobial Surveillance Program","author":"JMI Laboratories"},{"key":"2022090713493032300_dkac214-B29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.35772\/ghm.2019.01026","article-title":"Strategic approach for combating antimicrobial resistance (AMR)","volume":"1","author":"Inoue","year":"2019","journal-title":"Glob Health Med"},{"key":"2022090713493032300_dkac214-B30","article-title":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report. Early implementation","author":"WHO","year":"2020"},{"key":"2022090713493032300_dkac214-B31","article-title":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021","author":"WHO"},{"key":"2022090713493032300_dkac214-B32","article-title":"Menzies School of Health Research. Vietnam Pneumococcal Project"},{"key":"2022090713493032300_dkac214-B33","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkaa276","article-title":"Hospital surveillance predicts community pneumococcal antibiotic resistance in Vietnam","volume":"75","author":"Dai","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022090713493032300_dkac214-B34","article-title":"ENT hospital treatment guideline 2015"},{"key":"2022090713493032300_dkac214-B35","article-title":"CAP treatment guideline 2020","author":"Vietnam Respiratory Association"},{"key":"2022090713493032300_dkac214-B36","article-title":"Guidance for antibiotic use in hospital 2020","author":"Vietnam Medical Association"},{"key":"2022090713493032300_dkac214-B37","article-title":"AECOPD treatment guideline 2018","author":"Viet Nam Respiratory Association"},{"key":"2022090713493032300_dkac214-B38","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022090713493032300_dkac214-B39","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"2022090713493032300_dkac214-B40","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022090713493032300_dkac214-B41","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2011-200598","article-title":"British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011","volume":"66","author":"Harris","year":"2011","journal-title":"Thorax"},{"key":"2022090713493032300_dkac214-B42","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cid\/cis370","article-title":"IDSA Clinical Practice Guideline for acute bacterial rhinosinusitis in children and adults","volume":"54","author":"Chow","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022090713493032300_dkac214-B43","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1542\/peds.2012-3488","article-title":"The diagnosis and management of acute otitis media","volume":"131","author":"Lieberthal","year":"2013","journal-title":"Pediatrics"},{"key":"2022090713493032300_dkac214-B44","article-title":"NICE guideline cg191. Pneumonia in adults: diagnosis and management","author":"NICE"},{"key":"2022090713493032300_dkac214-B45","article-title":"Acute rhinosinutis in adults","author":"INESSS: Insitut national d\u2019excellence en sant\u00e9 et en services sociaux.","year":"2016"},{"key":"2022090713493032300_dkac214-B46","article-title":"Acute rhinosinusitis in children","author":"INESSS: Insitut national d\u2019excellence en sant\u00e9 et en services sociaux.","year":"2016"},{"key":"2022090713493032300_dkac214-B47","article-title":"Acute otitis media (AOM) in children 3 months of age or older","author":"INESSS: Insitut national d\u2019excellence en sant\u00e9 et en services sociaux.","year":"2016"},{"key":"2022090713493032300_dkac214-B48","article-title":"NICE guideline ng179. Sinusitis (acute): antimicrobial prescribing","author":"NICE"},{"key":"2022090713493032300_dkac214-B49","article-title":"Community- acquired pneumonia in adults","author":"INESSS 2017: Insitut national d'excellence en sant\u00e9 et en services sociaux","year":"2017"},{"key":"2022090713493032300_dkac214-B50","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090713493032300_dkac214-B51","article-title":"NICE guideline ng138. Pneumonia (community-acquired): antimicrobial prescribing","author":"NICE"},{"key":"2022090713493032300_dkac214-B52","article-title":"World Health Organization Model List of Essential Medicines","author":"WHO","year":"2019"},{"key":"2022090713493032300_dkac214-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal polyps","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"2022090713493032300_dkac214-B54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2022090713493032300_dkac214-B55","article-title":"Access barriers to antibiotics","author":"Frost","year":"2019"},{"key":"2022090713493032300_dkac214-B56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2471\/BLT.17.199562","article-title":"Medicines quality assurance to fight antimicrobial resistance","volume":"96","author":"Nwokike","year":"2018","journal-title":"Bull World Health Organ"},{"key":"2022090713493032300_dkac214-B57","article-title":"Substandard and falsified medical products","author":"WHO"},{"key":"2022090713493032300_dkac214-B58","article-title":"Amoxicillin+ clavulanic acid","author":"MIMS Vietnam"},{"key":"2022090713493032300_dkac214-B59","article-title":"Pneumonia (Community-Acquired)","author":"MIMS Vietnam"},{"key":"2022090713493032300_dkac214-B60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13756-021-00937-4","article-title":"Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017","volume":"10","author":"Vu","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022090713493032300_dkac214-B61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pds.3614","article-title":"Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country","volume":"24","author":"Trinh","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022090713493032300_dkac214-B62","first-page":"65","article-title":"Applying lessons learnt from research of child pneumonia management in Vietnam","volume":"39","author":"Nguyen","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"2022090713493032300_dkac214-B63","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.trstmh.2011.07.015","article-title":"Unnecessary antibiotic use for mild acute respiratory infections during 28-day follow-up of 823 children under five in rural Vietnam","volume":"105","author":"Nguyen","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2022090713493032300_dkac214-B64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2050-6511-15-6","article-title":"Antibiotic sales in rural and urban pharmacies in northern Vietnam: an observational study","volume":"15","author":"Nga","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2022090713493032300_dkac214-B65","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1186\/s12889-019-7812-z","article-title":"\u2018I can make more from selling medicine when breaking the rules\u2019\u2014understanding the antibiotic supply network in a rural community in Viet Nam","volume":"19","author":"Nguyen","year":"2019","journal-title":"BMC Public Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/Supplement_1\/i26\/45740936\/dkac214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/Supplement_1\/i26\/45740936\/dkac214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T06:20:03Z","timestamp":1676701203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/Supplement_1\/i26\/6692270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":65,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac214","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,6]]},"published":{"date-parts":[[2022,9,6]]}}}